BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 14619970)

  • 1. Present status of antileishmanial vaccines.
    Ghosh M; Bandyopadhyay S
    Mol Cell Biochem; 2003 Nov; 253(1-2):199-205. PubMed ID: 14619970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leishmaniasis: prevention, parasite detection and treatment.
    Kobets T; Grekov I; Lipoldova M
    Curr Med Chem; 2012; 19(10):1443-74. PubMed ID: 22360481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in vaccines for leishmaniasis.
    Requena JM; Iborra S; Carrión J; Alonso C; Soto M
    Expert Opin Biol Ther; 2004 Sep; 4(9):1505-17. PubMed ID: 15335317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leishmania vaccines: progress and problems.
    Kedzierski L; Zhu Y; Handman E
    Parasitology; 2006; 133 Suppl():S87-112. PubMed ID: 17274851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress towards a Leishmania vaccine.
    Tabbara KS
    Saudi Med J; 2006 Jul; 27(7):942-50. PubMed ID: 16830009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leishmaniasis.
    Kedzierski L
    Hum Vaccin; 2011 Nov; 7(11):1204-14. PubMed ID: 22048116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccines in leishmaniasis: advances in the last five years.
    Brodskyn C; de Oliveira CI; Barral A; Barral-Netto M
    Expert Rev Vaccines; 2003 Oct; 2(5):705-17. PubMed ID: 14711330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-generation vaccines against leishmaniasis.
    Coler RN; Reed SG
    Trends Parasitol; 2005 May; 21(5):244-9. PubMed ID: 15837614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Approaches and problems in vaccine development against leishmaniasis].
    Allahverdiyev A; Bağirova M; Cakir Koç R; Oztel ON; Elçıçek S; Ateş SC; Karaca TD
    Turkiye Parazitol Derg; 2010; 34(2):122-30. PubMed ID: 20597059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant DNA-derived leishmania proteins: from the laboratory to the field.
    Kubar J; Fragaki K
    Lancet Infect Dis; 2005 Feb; 5(2):107-14. PubMed ID: 15680780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of dendritic cell-based vaccine development for leishmaniasis.
    Bagirova M; Allahverdiyev AM; Abamor ES; Ullah I; Cosar G; Aydogdu M; Senturk H; Ergenoglu B
    Parasite Immunol; 2016 Nov; 38(11):651-662. PubMed ID: 27591404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunology of Leishmania infection and the implications for vaccine development.
    Vanloubbeeck Y; Jones DE
    Ann N Y Acad Sci; 2004 Oct; 1026():267-72. PubMed ID: 15604504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines for leishmaniasis: from proteome to vaccine candidates.
    Schroeder J; Aebischer T
    Hum Vaccin; 2011; 7 Suppl():10-5. PubMed ID: 21245661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leishmaniasis: current treatment and prospects for new drugs and vaccines.
    Kedzierski L; Sakthianandeswaren A; Curtis JM; Andrews PC; Junk PC; Kedzierska K
    Curr Med Chem; 2009; 16(5):599-614. PubMed ID: 19199925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meetings on vaccine studies towards the control of leishmaniasis. UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR) February 13-22 and April 4-5, 1995.
    Grimaldi Júnior G
    Mem Inst Oswaldo Cruz; 1995; 90(4):553-6. PubMed ID: 8551962
    [No Abstract]   [Full Text] [Related]  

  • 16. Leishmaniasis vaccine candidates for development: a global overview.
    Khamesipour A; Rafati S; Davoudi N; Maboudi F; Modabber F
    Indian J Med Res; 2006 Mar; 123(3):423-38. PubMed ID: 16778321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leishmaniasis: current status of vaccine development.
    Handman E
    Clin Microbiol Rev; 2001 Apr; 14(2):229-43. PubMed ID: 11292637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leishmanicidal activity of synthetic antimicrobial peptides in an infection model with human dendritic cells.
    Pérez-Cordero JJ; Lozano JM; Cortés J; Delgado G
    Peptides; 2011 Apr; 32(4):683-90. PubMed ID: 21262294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of nanotechnology in treatment of leishmaniasis: A Review.
    Akbari M; Oryan A; Hatam G
    Acta Trop; 2017 Aug; 172():86-90. PubMed ID: 28460833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leishmaniasis vaccination: targeting the source of infection.
    Reed SG
    J Exp Med; 2001 Aug; 194(3):F7-F9. PubMed ID: 11489957
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.